Abstract: Objective: Non – alcoholic fatty liver disease (NAFLD) is a sonological entity without alteration of liver enzymes. The insulin resistance is measured from homeostasis model assessment (HOMA) as (HOMA-IR), calculated from estimations of fasting glucose(mg/dl) x fasting insulin (U/l) /405.The purpose of this case – control study was to corelate C-reactive protein to non-alcoholic fatty liver disease with and without insulin resistance. Method: This study was done at the Department of Medicine,DR. PSIMS & RF Chinaoutpally, A.P. India between Jan 2012 to Dec 2012.1 200 patients (00 cases, 100 controls) above 18 years of age were included in this study. Results: The mean fasting insulin levels in cases were 14.71050+8.70280 statistically significant than controls 5.27556+3.65791 (p: 0.05). The mean HOMA IR levels in cases were 3.18 + 0.24statistically significant than controls 1.09 + 0.07 (p: < 0.05). The mean CRP levels in cases were 3.06 + 1.61statistically significant than controls 1.03 + 0.86 (p: 0.05). Conclusions: Patients with Non – alcoholic fatty liver disease with high fasting insulin levels and high insulin resistance have higher serum C-reactive protein levels than controls.
Key words: NAFLD, insulin resistance, C-reactive protein,
[1] Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;4: 917-923
[2] Kristina M. Utzschneider and Steven E. Kahn: The Role of Insulin Resistance in NonalcoholicFatty Liver Disease: The Journal of Clinical Endocrinology & Metabolism 91(12):4753– 4761
[3] Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K,Omatsu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J, Ida K2005The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143:722–728
[4] Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M,McCullough AJ, Natale S, Forlani G, Melchionda N2001 Nonalcoholic fattyliver disease: a feature of the metabolic syndrome. Diabetes 50:1844 –1850
[5] Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, Ponti V, Pagano G, Ferrannini E, Rizzetto M2005 Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 48:634 – 642
[6] Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A, Halavaara J, Yki-Jarvinen H2002 Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 87:3023–3028
[7] Flegal KM, Carroll MD, Ogden CL, Johnson CL2002 Prevalence and trends in obesity among US adults, 1999 –2000. JAMA 288:1723–1727
[8] Moran JR, Ghishan FK, Halter SA, Greene HL 1983 Steatohepatitis in obese children: a cause of chronic liver dysfunction. Am J Gastroenterol 78:374 –377
[9] Baldridge AD, Perez-Atayde AR, Graeme-Cook F, Higgins L, Lavine JE1995 Idiopathic steatohepatitis in childhood: a multicenter retrospective study.J Pediatr 127:700 –704
[10] Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC:Turner, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.